Scouting report · CMPS

Teri Loxam

COMPASS Pathways CFO since March 2024; ex-Merck IR head and three-time biotech CFO

Born / age
(54)
Role
Chief Financial Officer
In the role
3 yr
Education
MBA University of California, Irvine, Paul Merage School of Business
Front Office rank
not ranked yet
CMPS
COMPASS Pathways plcBiotech binary
Title
Chief Financial Officersrc
In role
since 2024-03 (3 yr)
Stake value—no holding or price on file
—thin record

Scouting sheetas of 25 Sep 2026

Delivers guidance—no promises on the record yet
Answers the question—no call reviewed yet
Capital allocation—company not reviewed yet
Pay design40strategic, individual, time only · 99.2% for · company lost money
Skin in the game—no holding or price on file
—Hit rate
—Pay at risk
99%Say-on-pay
—Airtime on calls
Beat
0
Met
0
Missed
0
Withdrawn
0
Still open
0
Answers on calls
0
Questions dodged
0
Dodges / 100 answers
—

Personal and ownership data

Full name
Teri Loxam
Age
54src
Education
MBA, University of California, Irvine, Paul Merage School of Businesssrc

Not on file yet: born, place of birth, citizenship, marital status.

Shares held
121,802 CMPS, 2026-04-06src
Share of company
0.09%
Traded, 12 months
bought $0, sold $0src
Last pay
$1.1m 2025src
Say-on-pay vote
99.2% forsrc

What to weigh

Watch 5

  • Three CFO jobs in the four years before COMPASS: SQZ (27 months), Kira (17 months) and Gameto (about 6 months)src
  • Chairs two outside public-company audit committees (Vaxcyte, Cardiol) while CFO of a company preparing its first NDA and launchsrc
  • Equity pay is time-vested options and RSUs with no performance condition. The 2025 bonus mixed corporate goals (scored 100%) with individual performancesrc
  • April 2025 amendment: all time-based equity vests in full on termination without cause or good-reason resignation within 12 months of a change in controlsrc
  • Owns 26,893 ADSs outright; with 94,909 exercisable options her holding is about 0.09%. No open-market trades in the last 12 monthssrc

Pay

Salary and otherBonus, stock, options, incentive

  • $2.3m2024
  • $1.1m2025
The table
YearSalaryBonusStockOptionsIncentiveOtherTotal
2024$388k$140k$720k$1.0m$0$69k$2.3msrc
2025$490k$220k$90k$274k$0$24k$1.1msrc
Bonus pays on
Cash bonus at a target of 45% of salary (cap 125% of target) on corporate goals plus individual performance. 2025 paid at 100% of target ($220,500)
Long-term award pays on
Annual market-priced options (76,000 in 2025) and RSUs (25,000). Time-vested, no performance conditionsrc
  • Pay at risk not on file
  • Pays on returns strategic, individual, time only
  • Shareholder vote 99.2% for
  • Pay vs profit company lost money

Career

  1. 2024-03 – now
    COMPASS Pathways plcsrc
    Chief Financial Officer
  2. 2023-12 – 2024-03
    COMPASS Pathways plcsrc
    Consultant / advisor ahead of CFO appointment
    Paid $54,958 in consulting fees
  3. 2023-04 – 2023-10
    Gameto, Inc. (private, clinical-stage biotech)src
    Chief Financial Officer
  4. 2021-11 – 2023-04
    Kira Pharmaceuticals (private, clinical-stage biotech)src
    Chief Financial Officer & Chief Operating Officer
  5. 2019-08 – 2021-11
    SQZ Biotechnologiessrc
    Chief Financial Officer
    Company bio credits her with leading SQZ's IPO and raising over $200m in her first 18 months (WS-bio)
  6. 2015-08 – 2019-08
    Merck & Co., Inc.src
    Various roles, including SVP Investor Relations & Global Communications
  7. 2012-07 – 2015-08
    IMAX Corporationsrc
    Vice President, Investor Relations
  8. 2001-06 – 2012-07
    Bristol-Myers Squibbsrc
    Roles of increasing responsibility across Strategy, Treasury and Investor Relations

Not located: 2023-10 to 2023-12, between Gameto and the COMPASS consulting role, not described; career before June 2001 not located beyond the company bio's statement that she began as a marine biologist

The promise ledger

No promise on the record yet: the research routine has not scored this company's guidance.

Background

  • Family The 2026 proxy states there are no family relationships among any directors or executive officerssrc
  • Boards Director and audit committee chair, Vaxcyte, Inc. (Nasdaq: PCVX), since September 2021src
  • Boards Director and audit committee chair, Cardiol Therapeutics Inc. (Nasdaq/TSX: CRDL), since May 2022src
  • Giving Board member of Warriorside, a veteran-founded nonprofit working on suicide, depression and disconnection among veterans and first responderssrc
  • Personal Says she began her career as a marine biologist before moving into businesssrc

Sources8